67 results on '"Park, Sophie"'
Search Results
2. DNA Replication Stress Due to Loss of R-Loops in Myelodysplastic Syndromes with SF3B1 Mutation
3. Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group
4. CPX 351 As First Line Treatment in Higher Risk MDS. a Phase II Trial By the GFM
5. Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) in Patients with IPSS Low or Intermediate-1 Myelodysplastic Syndrome (MDS): A Prospective Multicenter Phase II Study Based on Donor Availability By the GFM & SFGM-TC "MDS-ALLO-Risk"
6. Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the Emsco Randomized Phase 3 Dacota Trial
7. A Molecular-Based Response Prediction Model to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome and Severe Thrombocytopenia
8. Effect of Rap-536 on MDS PDX-Murine Models with or without SF3B1 Mutation
9. Biomarkers of Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - Results of the Europe Trial By the Emsco Network
10. Tumor microenvironment and clonal monocytes from chronic myelomonocytic leukemia induce a procoagulant climate
11. A Randomized Phase II Study of Azacitidine (AZA) Alone or with Lenalidomide (LEN), Valproic Acid (VPA) or Idarubicin (IDA) in Higher-Risk MDS: Gfm's 'pick a Winner' Trial
12. Mechanisms of Improvement of Erythropoiesis with Low Dose Deferasirox in Low Risk Myelodysplastic Syndromes
13. Results of a Phase II Study of Guadecitabine (SGI-110) in Higher Risk MDS, CMML or Low Blast Count AML Patients Refractory to or Relapsing after Azacitidine (AZA) Treatment
14. Impact of Treatment with Iron Chelators in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry
15. Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). a Report of 9 Cases
16. Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms
17. Prognostic Impact of Response According to International Consortium for MDS/MPN Criteria in CMML Treated with Hypomethylating Agents (HMA)
18. Efficacy of Azacitidine (AZA) in Autoimmune and Inflammatory Disorders (AID) Associated with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
19. A Phase I-II Study of the Efficacy and Safety of Lenalidomide (LEN) Combined to Azacitidine (AZA) in Higher Risk MDS and AML with Del 5q - a Study By the Groupe Francophone Des Myelodysplasies (GFM)
20. Outcome of Lower Risk Non Del 5q MDS after Failure of Erythropoiesis Stimulating Agents (ESA), and Impact of Post-ESA Treatment on Survival: A Retrospective European Study
21. A Two-Gene Classifier for Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Report By the GFM
22. Prognostic Impact of Transfusions Intensity on Survival and Development of Thrombocytopenia in Newly Diagnosed Lower-Risk MDS Patients Participating in the European Leukemianet EU-MDS Registry
23. Outcome of Patients Treated for Myelodysplastic Syndromes after Failure of Lenalidomide Therapy
24. MDS with Isolated Trisomy 8. a Type of MDS Frequently Associated with Myeloproliferative Features? A Report from the GFM
25. Efficacy and Safety of Darbepoetin Alfa (DA) in Patients with Myelodysplastic Syndromes (MDS): A Systematic Review and Meta-Analysis
26. Systemic Inflammatory and Autoimmune Diseases (SAID) Associated with MDS: A French Multicenter Retrospective Study
27. Treatment With Decitabine (DAC) After Azacitidine (AZA) Failure In High Risk Myelodysplastic Syndrome (MDS) and Advanced Chronic Myelomonocytic Leukemia (CMML)
28. The Revised IPSS (IPSS-R) Predicts Response To Erythropoietic Stimulating agents (ESA) In Pts With Classical IPSS Low Or Intermediate-1 (int 1)- MDS: A Joint Retrospective Study Of The GFM, Düsseldorf Registry and Fism
29. Prognostic Factors Of Response and Survival To Azacitidine (AZA) +/- EPO In RBC Transfusion Dependent (TD) IPSS Low and Int-1 (LR) MDS Resistant To EPO, With Particular Emphasis Of Genetic Lesions: A Study By The GFM
30. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders
31. Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?
32. Early Mortality in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European Leukemianet MDS (EUMDS) Registry
33. Is Azacitidine (AZA) Really Effective in High Risk MDS Patients with Chromosome 7 Abnormalities (Abn 7)? Results of a Retrospective Study From the GFM and GESMD Registries
34. Prognostic Factors of Response to Erythropoiesis Stimulating Agents (ESA) Treatment in Non RBC Transfusion Dependent Lower Risk MDS. Preliminary Results of a French and Italian Study (on behalf of the GFM and FISM).
35. BCOR Mutations Represent an Independent Factor of Poor Prognosis in Myelodysplastic Syndromes
36. RAD001: A Clinico-Biological Phase I GOELAMS trial of Everolimus Association with High Dose Chemotherapy in Late Relapsing AML Patients Under 65 Years of Age
37. A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS
38. Impact of Azacitidine (AZA) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) for Myelodysplastic Syndromes (MDS): A Large-Scale Study on Behalf of the SFGM-TC and GFM Groups
39. Transfusion-Dependency Is the Most Important Prognostic Factor for Survival in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European LeukemiaNet MDS Registry
40. Allogeneic Stem Cell Transplantation (allo-SCT) for Chronic Myelomonocytic Leukemia (CMML): Prognostic Factors for Survival. A Report From the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC),
41. Correlation Between serum ferritin Level at diagnosis and Survival In Lower Risk, Non-Transfusion Dependent, MDS Patients.A Report by the Groupe Francophone Des Myelodysplasies (GFM)
42. Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/− Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone
43. Final Results of the RiPAD+C Regimen Including Velcade In Front Line Therapy for Elderly Patients with Mantle Cell Lymphoma. A Phase II Prospective Study of the GOELAMS Group.
44. Long-Term Outcome of Anemic Non Del 5q Lower-Risk MDS Refractory to or Relapsing After Erythropoiesis Stimulating Agents (ESAs)
45. IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia
46. The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation
47. Early Treatment of Anemia of Lower Risk MDS by Erythropoiesis-Stimulating Agents (ESAs): A Report On 112 Cases.
48. The PI3K/mTOR Inhibitor NVP-BEZ235 Is a Promising Pre-Clinical Candidate for Therapeutic Intervention in Acute Myeloid Leukemia.
49. P-ERK1/2 Is a Predictive Factor of Response to ESA Treatment in Myelodysplastic Syndromes.
50. IκB Kinase Overcomes PI3K to Control FoxO3a Subcellular Localization in Acute Myeloid Leukemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.